Hemail M. Alsubaie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hemail M. Alsubaie has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Faisal R. Alzahrani
King Saud University Medical City
3 shared publications- Mohammad Ali Alessa
Head and Neck & Skull Base Health Center, King Abdullah Medical City, Makkah, Saudi Arabia
3 shared publications - Ahmed Abu-Zaid
Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia
2 shared publications - Ebraheem Albazee
Otorhinolaryngology-Head and Neck Surgery, Kuwait Institute for Medical Specializations (KIMS), Kuwait City, Kuwait
2 shared publications Khaled M. Alsubaie
Department of Surgery Alhada Armed Forces Hospital Taif Saudi Arabia
2 shared publications- Saad Alsaleh
Security Forces Hospitals Program, General Directorate of Medical Services, Ministry of Interior, Riyadh, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 9 January 2025
- Published by Wiley
Validation of the Arabic Version of ThyroidEx and its Reliability among Arabic-Speaking Patients Enduring Thyroid Surgery
Background: ThyroidEx is a 19-item self-reported outcome measure designed to evaluate the expectations related to thyroid surgery. This study intended to validate the Arabic version of the ThyroidEx and measure its reliability and applicability among Arabic-speaking patients undergoing total thyroidectomy. Methods: A prospective cohort study was conducted where the ThyroidEx questionnaire was translated into Arabic and culturally adapted. In contrast to the original study, we included only patients who underwent total thyroidectomy as it suits most of the questions within the measure, such as thyroid medications and hypocalcemia concerns, while those set to undergo hemithyroidectomy or completion thyroidectomy were excluded. Participants were asked to complete the Arabic ThyroidEx questionnaire before surgery and again after surgery. The internal consistency of the questionnaire was analyzed using Cronbach’s alpha. Results: Our study revealed that patient expectations regarding mood changes due to medication adjustments significantly increased after surgery, with a P-value of 0.012. While expectations about pain and fatigue remained consistent before and after surgery, there was a slight increase in the anticipation of fatigue postoperatively. Concerns about long-term medication use, side effects of thyroid medication, and cancer recurrence also heightened after surgery, reflecting growing patient anxiety in these areas. Conclusion: The findings underscore the importance of addressing mood changes, medication side effects, and long-term management in preoperative discussions. The significant shift in mood-related expectations and the stable reliability of the Arabic ThyroidEx questionnaire highlights its effectiveness in capturing patient concerns, which can guide better patient support and improve postoperative outcomes.
- 9 January 2025
- Published by Wiley
Open AccessValidation of the Arabic Version of ThyroidEx and its Reliability among Arabic-Speaking Patients Enduring Thyroid Surgery
Background: ThyroidEx is a 19-item self-reported outcome measure designed to evaluate the expectations related to thyroid surgery. This study intended to validate the Arabic version of the ThyroidEx and measure its reliability and applicability among Arabic-speaking patients undergoing total thyroidectomy. Methods: A prospective cohort study was conducted where the ThyroidEx questionnaire was translated into Arabic and culturally adapted. In contrast to the original study, we included only patients who underwent total thyroidectomy as it suits most of the questions within the measure, such as thyroid medications and hypocalcemia concerns, while those set to undergo hemithyroidectomy or completion thyroidectomy were excluded. Participants were asked to complete the Arabic ThyroidEx questionnaire before surgery and again after surgery. The internal consistency of the questionnaire was analyzed using Cronbach’s alpha. Results: Our study revealed that patient expectations regarding mood changes due to medication adjustments significantly increased after surgery, with a P-value of 0.012. While expectations about pain and fatigue remained consistent before and after surgery, there was a slight increase in the anticipation of fatigue postoperatively. Concerns about long-term medication use, side effects of thyroid medication, and cancer recurrence also heightened after surgery, reflecting growing patient anxiety in these areas. Conclusion: The findings underscore the importance of addressing mood changes, medication side effects, and long-term management in preoperative discussions. The significant shift in mood-related expectations and the stable reliability of the Arabic ThyroidEx questionnaire highlights its effectiveness in capturing patient concerns, which can guide better patient support and improve postoperative outcomes.
- Open Access
- 6 August 2024
- Published by Wiley in Head & Neck
- Vol. 46 (10) , 2632-2649
The effectiveness of neck stretching exercises in alleviating neck pain and self‐reported disability after thyroidectomy: A systematic review and meta‐analysis of clinical trials
Thyroidectomy can lead to significant challenges such as neck pain, disability, and limited range of motion. Therefore, our objective is to conduct a systematic review and meta‐analysis of clinical trials to investigate the clinical effectiveness of neck stretching exercises in alleviating neck pain and self‐reported disability immediately after thyroidectomy. We systematically searched PubMed, CENTRAL, Scopus, and Web of Science from inception until July 28th, 2023. We assessed the selected trials for the risk of bias using both the RoB‐2 and ROBINS‐I tools. Our specific outcomes were the severity of neck pain and self‐reported disability after thyroidectomy. The results were synthesized using risk ratio (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) in a random‐effects model using Stata software. Nine clinical trials, comprising five randomized and four non‐randomized trials, were included, with a total of 1026 patients. Neck stretching exercises were significantly associated with improved mean pain scores both after 1 week (n = 625 patients, SMD = −2.43, 95% CI [−4.65, −0.22], p = 0.03, I2 = 98%) and 1 month (n = 545 patients, SMD = −4.11, 95% CI [−8.12, −0.11], p = 0.04, I2 = 99%). Similarly, neck stretching exercises were significantly associated with improved mean self‐reported disability scores both after 1 week (n = 298 patients, SMD = −0.70, 95% CI [−1.36, −0.04], p = 0.04, I2 = 87%) and 1 month (n = 298 patients, SMD = −0.42, 95% CI [−0.65, −0.19], p = 0.0004, I2 = 0%). The pooled analysis showed heterogeneity (chi‐square p < 0.01, I2 > 80%), except for the mean self‐reported neck disability score after 1 month, which showed homogeneity (chi‐square p > 0.01, I2 = 0%). This systematic review and meta‐analysis, involving 1026 patients, revealed the potential benefits of neck stretching exercises in alleviating neck pain and self‐reported disability after thyroidectomy. However, further research is required to address methodological limitations, evaluate long‐term outcomes, investigate potential moderators (i.e., the duration or intensity of the exercise program), and explore patients' analgesic consumption.
- 6 August 2024
- Published by Wiley in Head & Neck
- Vol. 46 (10) , 2632-2649
Open AccessThe effectiveness of neck stretching exercises in alleviating neck pain and self‐reported disability after thyroidectomy: A systematic review and meta‐analysis of clinical trials
Thyroidectomy can lead to significant challenges such as neck pain, disability, and limited range of motion. Therefore, our objective is to conduct a systematic review and meta‐analysis of clinical trials to investigate the clinical effectiveness of neck stretching exercises in alleviating neck pain and self‐reported disability immediately after thyroidectomy. We systematically searched PubMed, CENTRAL, Scopus, and Web of Science from inception until July 28th, 2023. We assessed the selected trials for the risk of bias using both the RoB‐2 and ROBINS‐I tools. Our specific outcomes were the severity of neck pain and self‐reported disability after thyroidectomy. The results were synthesized using risk ratio (RR) and standardized mean differences (SMD) with 95% confidence intervals (CI) in a random‐effects model using Stata software. Nine clinical trials, comprising five randomized and four non‐randomized trials, were included, with a total of 1026 patients. Neck stretching exercises were significantly associated with improved mean pain scores both after 1 week (n = 625 patients, SMD = −2.43, 95% CI [−4.65, −0.22], p = 0.03, I2 = 98%) and 1 month (n = 545 patients, SMD = −4.11, 95% CI [−8.12, −0.11], p = 0.04, I2 = 99%). Similarly, neck stretching exercises were significantly associated with improved mean self‐reported disability scores both after 1 week (n = 298 patients, SMD = −0.70, 95% CI [−1.36, −0.04], p = 0.04, I2 = 87%) and 1 month (n = 298 patients, SMD = −0.42, 95% CI [−0.65, −0.19], p = 0.0004, I2 = 0%). The pooled analysis showed heterogeneity (chi‐square p < 0.01, I2 > 80%), except for the mean self‐reported neck disability score after 1 month, which showed homogeneity (chi‐square p > 0.01, I2 = 0%). This systematic review and meta‐analysis, involving 1026 patients, revealed the potential benefits of neck stretching exercises in alleviating neck pain and self‐reported disability after thyroidectomy. However, further research is required to address methodological limitations, evaluate long‐term outcomes, investigate potential moderators (i.e., the duration or intensity of the exercise program), and explore patients' analgesic consumption.
- 30 May 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (5) , 567-577
Platelet‐rich plasma following endoscopic sinus surgery in patients with chronic sinusitis: A systematic review and meta‐analysis of randomised controlled trials
Introduction: To comprehensively evaluate the reported clinical effectiveness of platelet‐rich plasma (PRP) in patients with chronic sinusitis undergoing endoscopic sinus surgery (ESS).Methods: We performed a systematic review and meta‐analysis of randomised controlled trials (RCTs). Five digital online databases (PubMed, Scopus, Web of Science, Google Scholar and Cochrane CENTRAL) were searched from inception up to 1st May 2023. Our specific outcomes involved postoperative nasal endoscopy scores measured via Lund‐Kennedy score or Meltzer score, olfactory sensation scores and pre‐operative anosmia duration. All data were pooled as standardised mean difference (SMD) with a 95% confidence interval (CI), using the RevMan software.Results: Six RCTs were included in this systematic review and meta‐analysis, with a total of 169 patients. The risk of bias in the included RCTs was low in three RCTs, some concerns in one RCT and high risk in two RCTs. The overall analysis of the postoperative nasal endoscopy scores showed that the PRP group had lower scores compared to the control group (n = 3 RCTs, SMD = −1.19; 95% CI [−1.94, −0.44], p = .002). There was no significant difference between the PRP and control groups regarding anosmia duration (n = 2 RCTs, SMD = 0.21; 95% CI [−0.17, 0.59], p = 0.28) or olfactory sensation scores, despite the PRP group having higher scores (n = 2 RCTs, SMD = 0.53; 95% CI [−0.32, 1.39], p = 0.22).Conclusion: This study highlights the potential advantages of using PRP as an additional treatment for individuals with chronic sinusitis undergoing ESS. The improvements associated with PRP include facilitating wound healing, reducing inflammation and enhancing surgical outcomes. To optimise the use of PRP in clinical settings, future research should focus on conducting larger trials with standardised protocols.
- 30 May 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (5) , 567-577
Platelet‐rich plasma following endoscopic sinus surgery in patients with chronic sinusitis: A systematic review and meta‐analysis of randomised controlled trials
Introduction: To comprehensively evaluate the reported clinical effectiveness of platelet‐rich plasma (PRP) in patients with chronic sinusitis undergoing endoscopic sinus surgery (ESS).Methods: We performed a systematic review and meta‐analysis of randomised controlled trials (RCTs). Five digital online databases (PubMed, Scopus, Web of Science, Google Scholar and Cochrane CENTRAL) were searched from inception up to 1st May 2023. Our specific outcomes involved postoperative nasal endoscopy scores measured via Lund‐Kennedy score or Meltzer score, olfactory sensation scores and pre‐operative anosmia duration. All data were pooled as standardised mean difference (SMD) with a 95% confidence interval (CI), using the RevMan software.Results: Six RCTs were included in this systematic review and meta‐analysis, with a total of 169 patients. The risk of bias in the included RCTs was low in three RCTs, some concerns in one RCT and high risk in two RCTs. The overall analysis of the postoperative nasal endoscopy scores showed that the PRP group had lower scores compared to the control group (n = 3 RCTs, SMD = −1.19; 95% CI [−1.94, −0.44], p = .002). There was no significant difference between the PRP and control groups regarding anosmia duration (n = 2 RCTs, SMD = 0.21; 95% CI [−0.17, 0.59], p = 0.28) or olfactory sensation scores, despite the PRP group having higher scores (n = 2 RCTs, SMD = 0.53; 95% CI [−0.32, 1.39], p = 0.22).Conclusion: This study highlights the potential advantages of using PRP as an additional treatment for individuals with chronic sinusitis undergoing ESS. The improvements associated with PRP include facilitating wound healing, reducing inflammation and enhancing surgical outcomes. To optimise the use of PRP in clinical settings, future research should focus on conducting larger trials with standardised protocols.
- Open Access
- 1 January 2024
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 32 (1) , 101885
Efficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia
To assess the efficacy and safety of the induction chemotherapy's combination of docetaxel, cisplatin, and 5-fluorouracil (TPF) in Oral Squamous Cell Carcinoma (OSCC) patients and its positive outcomes on tumor size and surgical resection. A retrospective chart review of patient's medical records was conducted from 2018 to 2023. All patients diagnosed with OSCC and who received induction chemotherapy combination of TPF were included in the study. Patients with other conditions that affect chemotherapy tolerability, other primary malignancy, or incomplete medical records were excluded. Descriptive analysis was undertaken to summarize the data pertaining to tumors before and after administration of the TPF chemotherapy. Five patients met the inclusion criteria. All five patients experienced a reduction in tumor size after receiving the TPF induction chemotherapy. Three patients showed a downstaging to [stage 0] after surgical resection. Specifically, one patient demonstrated a reduction in overall stage from [IVb] to [IVa] after receiving TPF induction chemotherapy, and two patients demonstrated a noteworthy improvement in N staging, reducing from [N2c] to [N2b]. In contrast, the fourth patient slightly improved after the induction chemotherapy and surgical resection procedures. However, the stage of the fifth patient remained unchanged before and after the treatment approach. The study shows that implementing TPF induction chemotherapy to surgical resection improves clinical outcomes in a subset of patients with advanced OSCC without any harmful consequences.
- 1 January 2024
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 32 (1) , 101885
Open AccessEfficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia
To assess the efficacy and safety of the induction chemotherapy's combination of docetaxel, cisplatin, and 5-fluorouracil (TPF) in Oral Squamous Cell Carcinoma (OSCC) patients and its positive outcomes on tumor size and surgical resection. A retrospective chart review of patient's medical records was conducted from 2018 to 2023. All patients diagnosed with OSCC and who received induction chemotherapy combination of TPF were included in the study. Patients with other conditions that affect chemotherapy tolerability, other primary malignancy, or incomplete medical records were excluded. Descriptive analysis was undertaken to summarize the data pertaining to tumors before and after administration of the TPF chemotherapy. Five patients met the inclusion criteria. All five patients experienced a reduction in tumor size after receiving the TPF induction chemotherapy. Three patients showed a downstaging to [stage 0] after surgical resection. Specifically, one patient demonstrated a reduction in overall stage from [IVb] to [IVa] after receiving TPF induction chemotherapy, and two patients demonstrated a noteworthy improvement in N staging, reducing from [N2c] to [N2b]. In contrast, the fourth patient slightly improved after the induction chemotherapy and surgical resection procedures. However, the stage of the fifth patient remained unchanged before and after the treatment approach. The study shows that implementing TPF induction chemotherapy to surgical resection improves clinical outcomes in a subset of patients with advanced OSCC without any harmful consequences.
- 27 July 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (11) , E66
In Response to Prophylactic Central Neck Dissection for Clinically Node‐Negative Papillary Thyroid Carcinoma
- 27 July 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (11) , E66
In Response to Prophylactic Central Neck Dissection for Clinically Node‐Negative Papillary Thyroid Carcinoma
- Open Access
- 30 May 2022
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 104 (4) , 204-206
Pregnancy-Related Giant Nasal Mass: A Diagnostic Dilemma
Significance Statement: Pregnancy-related giant nasal masses often present a diagnostic challenge and clinical dilemma due to the obvious restrictions in utilizing imaging and general anesthesia during pregnancy. Therefore, we highlight the importance of clinical judgment, especially during pregnancy, and should not disregard certain clinical cues. In addition, we recommend an in-office polypectomy for giant nasal polyps worsening during pregnancy and nasal steroids to optimize their quality of life while avoiding systemic medications or further interventions.
- 30 May 2022
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 104 (4) , 204-206
Open AccessPregnancy-Related Giant Nasal Mass: A Diagnostic Dilemma
Significance Statement: Pregnancy-related giant nasal masses often present a diagnostic challenge and clinical dilemma due to the obvious restrictions in utilizing imaging and general anesthesia during pregnancy. Therefore, we highlight the importance of clinical judgment, especially during pregnancy, and should not disregard certain clinical cues. In addition, we recommend an in-office polypectomy for giant nasal polyps worsening during pregnancy and nasal steroids to optimize their quality of life while avoiding systemic medications or further interventions.
- 28 October 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1320-1328
Prophylactic Central Neck Dissection for Clinically Node‐Negative Papillary Thyroid Carcinoma
Objective: We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) that scrutinized the oncological benefits and postsurgical complications of total thyroidectomy (TT) plus prophylactic central neck dissection (pCND) versus TT alone among clinically node‐negative (cN0) papillary thyroid cancer (PTC) patients.Methods: We screened five databases from inception to September 4, 2021 and evaluated the risk of bias of the eligible studies. We pooled dichotomous outcomes using the risk ratio (RR) with 95% confidence interval (CI).Results: Overall, we included 5 RCTs with low risk of bias comprising 795 patients (TT plus pCND = 410 and TT alone = 385). With regard to efficacy endpoint, the rate of structural loco‐regional recurrence did not significantly differ between both groups (n = 4 RCTs, RR = 0.49, 95% CI [0.19, 1.27], P = .14). With regard to safety endpoints, the rates of hypoparathyroidism (n = 5 RCTs, RR = 1.48, 95% CI [0.73, 2.97], P = .27), recurrent laryngeal nerve injury (n = 5 RCTs, RR = 1.34, 95% CI [0.59, 3.03], P = .48), and bleeding (n = 3 RCTs, RR = 1.75, 95% CI [0.42, 7.26], P = .44) did not significantly differ between both groups.Conclusion: For cN0 PTC patients, there was no significant difference between TT plus pCND and TT alone with regard to the rate of structural loco‐regional recurrence or frequency of postsurgical complications. Adaptation of pCND in cN0 PTC patients should be contemplated by taking into consideration the clinical oncological benefits and rate of postsurgical adverse events.Level of Evidence: 1 Laryngoscope, 132:1320–1328, 2022
- 28 October 2021
- Published by Wiley in The Laryngoscope
- Vol. 132 (6) , 1320-1328
Prophylactic Central Neck Dissection for Clinically Node‐Negative Papillary Thyroid Carcinoma
Objective: We performed a systematic review and meta‐analysis of randomized controlled trials (RCTs) that scrutinized the oncological benefits and postsurgical complications of total thyroidectomy (TT) plus prophylactic central neck dissection (pCND) versus TT alone among clinically node‐negative (cN0) papillary thyroid cancer (PTC) patients.Methods: We screened five databases from inception to September 4, 2021 and evaluated the risk of bias of the eligible studies. We pooled dichotomous outcomes using the risk ratio (RR) with 95% confidence interval (CI).Results: Overall, we included 5 RCTs with low risk of bias comprising 795 patients (TT plus pCND = 410 and TT alone = 385). With regard to efficacy endpoint, the rate of structural loco‐regional recurrence did not significantly differ between both groups (n = 4 RCTs, RR = 0.49, 95% CI [0.19, 1.27], P = .14). With regard to safety endpoints, the rates of hypoparathyroidism (n = 5 RCTs, RR = 1.48, 95% CI [0.73, 2.97], P = .27), recurrent laryngeal nerve injury (n = 5 RCTs, RR = 1.34, 95% CI [0.59, 3.03], P = .48), and bleeding (n = 3 RCTs, RR = 1.75, 95% CI [0.42, 7.26], P = .44) did not significantly differ between both groups.Conclusion: For cN0 PTC patients, there was no significant difference between TT plus pCND and TT alone with regard to the rate of structural loco‐regional recurrence or frequency of postsurgical complications. Adaptation of pCND in cN0 PTC patients should be contemplated by taking into consideration the clinical oncological benefits and rate of postsurgical adverse events.Level of Evidence: 1 Laryngoscope, 132:1320–1328, 2022
- 18 October 2021
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 279 (5) , 2231-2238
Tranexamic acid in head and neck procedures: a systematic review and meta-analysis of randomized controlled trials
Objective We conducted a meta-analysis of all randomized controlled trials (RCTs) that examined the benefits of tranexamic acid (TXA) among cancer patients undergoing head and neck (H&N) procedures. Methods We screened five databases from inception until 20 June 2021 and evaluated the risk of bias of the eligible studies. We pooled continuous outcomes using the weighted mean difference (WMD) with 95% confidence interval (CI). Results Five studies, comprising seven RCTs, met the inclusion criteria. This meta-analysis included a total of 540 patients; 265 and 275 patients were assigned to the TXA and control group, respectively. Overall, the included RCTs revealed a low risk of bias. The volume of postoperative bleeding was significantly lower in favor of the TXA group compared with the control group (n = 7 RCTs, WMD = − 51.33 ml, 95% CI [− 101.47 to − 1.2], p = 0.04). However, no significant difference was found between both groups regarding the volume of intraoperative bleeding (n = 6 RCTs, WMD = − 3.48 ml, 95% CI [− 17.11 to 10.15], p = 0.62), postoperative hemoglobin (n = 3 RCTs, WMD = 0.42 mg/dl, 95% CI [− 0.27 to 1.11], p = 0.23), duration of drainage tube removal (n = 4 RCTs, MD = − 0.41 days, 95% CI [− 1.14 to 0.32], p = 0.27), and operation time (n = 6 RCTs, WMD = 1.59 min, 95% CI [− 10.09 to 13.27], p = 0.79). TXA was safe and did not culminate in thromboembolic events or major coagulation derangements. Conclusion TXA administration is safe and significantly reduces the volume of postoperative bleeding. However, no difference is identified between TXA and control groups regarding the volume of intraoperative bleeding, postoperative hemoglobin level, duration of drainage tube removal, and operation time.
- 18 October 2021
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 279 (5) , 2231-2238
Tranexamic acid in head and neck procedures: a systematic review and meta-analysis of randomized controlled trials
Objective We conducted a meta-analysis of all randomized controlled trials (RCTs) that examined the benefits of tranexamic acid (TXA) among cancer patients undergoing head and neck (H&N) procedures. Methods We screened five databases from inception until 20 June 2021 and evaluated the risk of bias of the eligible studies. We pooled continuous outcomes using the weighted mean difference (WMD) with 95% confidence interval (CI). Results Five studies, comprising seven RCTs, met the inclusion criteria. This meta-analysis included a total of 540 patients; 265 and 275 patients were assigned to the TXA and control group, respectively. Overall, the included RCTs revealed a low risk of bias. The volume of postoperative bleeding was significantly lower in favor of the TXA group compared with the control group (n = 7 RCTs, WMD = − 51.33 ml, 95% CI [− 101.47 to − 1.2], p = 0.04). However, no significant difference was found between both groups regarding the volume of intraoperative bleeding (n = 6 RCTs, WMD = − 3.48 ml, 95% CI [− 17.11 to 10.15], p = 0.62), postoperative hemoglobin (n = 3 RCTs, WMD = 0.42 mg/dl, 95% CI [− 0.27 to 1.11], p = 0.23), duration of drainage tube removal (n = 4 RCTs, MD = − 0.41 days, 95% CI [− 1.14 to 0.32], p = 0.27), and operation time (n = 6 RCTs, WMD = 1.59 min, 95% CI [− 10.09 to 13.27], p = 0.79). TXA was safe and did not culminate in thromboembolic events or major coagulation derangements. Conclusion TXA administration is safe and significantly reduces the volume of postoperative bleeding. However, no difference is identified between TXA and control groups regarding the volume of intraoperative bleeding, postoperative hemoglobin level, duration of drainage tube removal, and operation time.
- 24 August 2021
- Published by Springer Nature in Dysphagia
- Vol. 37 (4) , 946-953
Validity and Reliability of an Arabic Version of MD Anderson Dysphagia Inventory (MDADI)
Dysphagia is a common adverse event among head and neck (H&N) cancer patients. We aimed, for the first time, to validate the Arabic version of the MD Anderson Dysphagia Inventory (MDADI) among 82 Saudi Arabian patients with H&N cancer. We followed established validation guidelines and translated the 20-item MDADI using the forward–backward method. Our results revealed 100% feasibility. Test–retest reliability demonstrated acceptable interclass correlation coefficients (ICC) for the subscale domains (emotional = 0.973, physical = 0.971, and functional = 0.956) and composite score (ICC = 0.984). The Cronbach’s alpha coefficients for the emotional, functional, and physical subscales were 0.937, 0.825, and 0.945, respectively (composite score = 0.975). We confirmed concurrent validity by demonstrating significant correlations between the domains of the Arabic MDADI and European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Head and Neck Module (QLQ-H&N35). Our study validated the Arabic version of the MDADI among H&N cancer patients from Saudi Arabia.
- 24 August 2021
- Published by Springer Nature in Dysphagia
- Vol. 37 (4) , 946-953
Validity and Reliability of an Arabic Version of MD Anderson Dysphagia Inventory (MDADI)
Dysphagia is a common adverse event among head and neck (H&N) cancer patients. We aimed, for the first time, to validate the Arabic version of the MD Anderson Dysphagia Inventory (MDADI) among 82 Saudi Arabian patients with H&N cancer. We followed established validation guidelines and translated the 20-item MDADI using the forward–backward method. Our results revealed 100% feasibility. Test–retest reliability demonstrated acceptable interclass correlation coefficients (ICC) for the subscale domains (emotional = 0.973, physical = 0.971, and functional = 0.956) and composite score (ICC = 0.984). The Cronbach’s alpha coefficients for the emotional, functional, and physical subscales were 0.937, 0.825, and 0.945, respectively (composite score = 0.975). We confirmed concurrent validity by demonstrating significant correlations between the domains of the Arabic MDADI and European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Head and Neck Module (QLQ-H&N35). Our study validated the Arabic version of the MDADI among H&N cancer patients from Saudi Arabia.
- 9 July 2021
- Published by Wiley in Head & Neck
- Vol. 43 (10) , 3199-3213
Glutamine for prevention and alleviation of radiation‐induced oral mucositis in patients with head and neck squamous cell cancer: Systematic review and meta‐analysis of controlled trials
We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) that investigated glutamine efficacy in preventing and alleviating radiation‐induced oral mucositis (OM) among patients with head and neck (H&N) cancer. We screened five databases from inception till February 4, 2021 and followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. We included 11 RCTs, comprising 922 patients (458 and 464 patients were assigned to glutamine and control group, respectively). The incidence and onset of radiation‐induced OM of any grade did not substantially differ between both groups. However, glutamine substantially reduced the severity of radiation‐induced OM, as reflected by the reduced incidence of severe OM and reduced mean maximal OM grade score. Additionally, glutamine significantly decreased the rates of analgesic opioid use, nasogastric tube feeding, and therapy interruptions. Oral glutamine supplementation demonstrated various therapeutic benefits in preventing and ameliorating radiation‐induced OM among patients with H&N cancer.
- 9 July 2021
- Published by Wiley in Head & Neck
- Vol. 43 (10) , 3199-3213
Glutamine for prevention and alleviation of radiation‐induced oral mucositis in patients with head and neck squamous cell cancer: Systematic review and meta‐analysis of controlled trials
We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) that investigated glutamine efficacy in preventing and alleviating radiation‐induced oral mucositis (OM) among patients with head and neck (H&N) cancer. We screened five databases from inception till February 4, 2021 and followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. We included 11 RCTs, comprising 922 patients (458 and 464 patients were assigned to glutamine and control group, respectively). The incidence and onset of radiation‐induced OM of any grade did not substantially differ between both groups. However, glutamine substantially reduced the severity of radiation‐induced OM, as reflected by the reduced incidence of severe OM and reduced mean maximal OM grade score. Additionally, glutamine significantly decreased the rates of analgesic opioid use, nasogastric tube feeding, and therapy interruptions. Oral glutamine supplementation demonstrated various therapeutic benefits in preventing and ameliorating radiation‐induced OM among patients with H&N cancer.